|
DOCS ICON Resourcing Solutions |
¿Ü±¹°è CRO- Jr. CRA (5¸í ä¿ë)
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
1³â¡è |
ä¿ë½Ã |
09.21 |
|
|
(ÁÖ)´ºÆ®¸®¹ÙÀÌ¿ÀÅØ |
(ÁÖ)´ºÆ®¸®¹ÙÀÌ¿ÀÅØ »ý»ê±âȹ °ü¸® °æ·Â ¸ðÁý
°æ±â ÀÌõ½Ã | Çз¹«°ü |
»ý»ê/»ý»ê°ü¸® |
4³â¡è |
ä¿ë½Ã |
03.14 |
|
|
IMS Health Korea |
Account Manager ¹× Marketing Specialist(OncologyºÐ¾ß) ¸ð
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
3³â¡è |
ä¿ë½Ã |
09.12 |
|
|
PharmaNet |
[Global CRO PharmaNet] °æ·Â CRA ±¸ÀÎ
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
03.30 |
|
|
(ÁÖ)ÄھƽºÆ®·Ð |
ÀÇ·á±â±â A/S ¿£Áö´Ï¾î ¸ðÁý
¼¿ï °³²±¸ | °íµîÇб³ |
AS/Á¤ºñ/¼ö¸®/¼³Ä¡ |
°æ·Â¹«°ü |
ä¿ë½Ã |
05.14 |
|
|
(ÁÖ)´ºÆ®¸®¹ÙÀÌ¿ÀÅØ |
(ÁÖ)´ºÆ®¸®¹ÙÀÌ¿ÀÅØ ÇØ¿Ü¿µ¾÷ °æ·ÂÀÚ ¸ðÁý
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¹«¿ª/ÇØ¿Ü¿µ¾÷/Åë¹ø¿ª |
5³â¡è |
ä¿ë½Ã |
12.28 |
|
|
DOCS ICON Resourcing Solutions |
¿Ü±¹°èCRO-Project Manager
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
|
°æ·Â¹«°ü |
ä¿ë½Ã |
09.02 |
|
|
(ÁÖ)ÀâÇ÷¯½º |
(ÁÖ5ÀÏ/¿Ü±¹°è±â¾÷)ÀÇ·á±â±â¹°·ù°ü¸® »ç¹«Á÷»ç¿ø¸ðÁý(°³²/
¼¿ï °³²±¸ | Çз¹«°ü |
¹«¿ª/ÇØ¿Ü¿µ¾÷/Åë¹ø¿ª |
°æ·Â¹«°ü |
ä¿ë½Ã |
07.07 |
|
|
½ÌÅ©ÅÊÅ©(ÁÖ) |
¿Ü±¹°èÁ¦¾àȸ»ç ÀÓ»ó±âȹ °æ·ÂÀÚ Ã¤¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
1³â¡è |
ä¿ë½Ã |
02.15 |
|
|
DOCS ICON Resourcing Solutions |
¿Ü±¹°è CRO-Study Authorization Associate (1¸í)
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
09.23 |
|
|
ICON Clinical Research Korea |
Jr. Clinical Research Associate(Oncology)
¼¿ï °³²±¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
04.22 |
|
|
ICON Clinical Research Korea |
Study Start-up Associate
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
04.22 |
|
|
µå¸²¼Ö·ç¼Ç |
30³â ÀÇ·á±â±â¾÷ ¿¬±¸¼Ò SMPS,FW,¾Æ³¯·Î±×HW °³¹ß °æ·ÂÁ÷ Ãæ
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
3³â¡è |
ä¿ë½Ã |
03.06 |
|
|
´ëȱâ±â(ÁÖ) |
ÀÇ·á±â±â ±â¼ú¿µ¾÷ ´ã´çÀÚ Á¤±ÔÁ÷
¼¿ï °³²±¸ | °íµîÇб³ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
°æ·Â¹«°ü |
ä¿ë½Ã |
12.05 |
|
|
¾ÆÇÁ·Î¸Þµð¿Â |
¾ÆÇÁ·Î¸Þµð¿Â ±¹³» º´¿ø¿µ¾÷ÆÀ(¼¿ï/°æ±â) + ¸¶ÄÉÆÃÆÀ
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
°æ·Â¹«°ü |
ä¿ë½Ã |
05.17 |
|